AstraZeneca shares results from ZENITH-CKD phase 2b trial for chronic kidney disease and proteinuria treatment
AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of zibotentan with dapagliflozin for the treatment of patients with chronic kidney disease (CKD) and proteinuria.
This combination demonstrated statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ration (UACR), used to assess albuminuria, at 12 weeks when compared to treatment with dapagliflozin alone.
These results were presented at the American Society of Nephrology (ASN) Kidney Week 2023 as well as having been published in The Lancet.
Sharon Barr, executive vice president of BioPharmaceuticals Research and Development at AstraZeneca, commented: “Despite current treatment options, residual proteinuria persists in a sizeable portion of patients and is associated with a high risk of kidney failure. The evidence published today supports advancement of zibotentan/dapagliflozin into a phase 3 clinical trial to further assess its potential as a first-in-class treatment for residual proteinuria in CKD.”
The company plans to progress the drug combination to a phase 3 trial; it is intended that this will begin in the final quarter of 2023.
AstraZeneca has announced that it has launched Evinova, its new health-tech business, which it is …
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) …